A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL (clinicaltrials.gov) - Oct 23, 2026 - P1/2 | N=32 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jul 2026 ➔ Dec 2026
Trial completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology
|